First patient dosed in second Phase 2 add-on Ketamine Trial

Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy,...

Related Keywords

Switzerland , Germany , South Africa , Australia , Pratteln , Switzerland General , Munich , Bayern , Schopfheim , Baden Wüberg , German , Swiss , Anne Donohoe , Sophia Bashford , Develco Pharma , Alexander Schmidt Europe , Hans Eriksson , Ketabon Program , Holding Gmb , Brain Health , Treatment Resistant Depression , Chief Medical Officer , Swiss Based Develco Pharma , Depression Rating Scale , Major Depressive Disorder , Hmnc Holding Gmbh ,